Azione ARVN ARVINAS, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Arvinas, Inc.

Azioni

ARVN

US04335A1051

Mercato chiuso - Nasdaq
Altri mercati azionari
 22:00:00 30/04/2024 		Variaz. 5gg Var. 1 gen.
31,77 USD -0,41% Grafico intraday di Arvinas, Inc. -6,56% -22,81%
24/04 Arvinas, Inc. nomina Randy Teel come Chief Business Officer CI
15/04 ARVINAS, INC. : giudizio positivo da HC Wainwright ZM

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
Arvinas, Inc. Appoints Randy Teel as Chief Business Officer
Arvinas : 2024 Proxy Statement
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Novartis : accord de licence dans le cancer de la prostate
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis
Novartis étend sa recherche contre le cancer de la prostate
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact
Novartis erweitert Pipeline mit Lizenzabkommen für Prostatakrebs-Kandidaten
Novartis licenses Arvinas' cancer drug for up to $1 billion
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer
Arvinas Appoints Noah Berkowitz as Chief Medical Officer
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee
Arvinas to Participate in Upcoming Investor Conferences
Arvinas' Q4 Net Loss Widens as Company Reports No Revenue
Arvinas, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione ARVN
  4. Notizie Arvinas, Inc.
  5. Altre lingue